Entero Therapeutics, Inc. financial data

Symbol
ENTO on Nasdaq
Location
777 Yamato Road, Suite 502, Boca Raton, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 19, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 283 % -36.8%
Debt-to-equity -1.45K % -1445%
Return On Equity 973 %
Return On Assets -16 % -8.92%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.36M shares
Common Stock, Shares, Outstanding 2.55M shares -46.3%
Entity Public Float 3.6M USD -46.3%
Common Stock, Value, Issued 255 USD -46.2%
Weighted Average Number of Shares Outstanding, Basic 1.65M shares +8.92%
Weighted Average Number of Shares Outstanding, Diluted 1.65M shares +8.92%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense -44.2K USD -102%
General and Administrative Expense 3.64M USD -77.5%
Operating Income (Loss) -3.6M USD +80.6%
Nonoperating Income (Expense) -189K USD -1206%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -971K USD +48.8%
Income Tax Expense (Benefit) 4.26M USD
Net Income (Loss) Attributable to Parent -15.6M USD -57.7%
Earnings Per Share, Basic -4 USD/shares -112%
Earnings Per Share, Diluted -1 USD/shares -104%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.52M USD +586%
Accounts Receivable, after Allowance for Credit Loss, Current 37.5K USD
Other Assets, Current 1.52M USD
Assets, Current 87.7M USD +4.6%
Property, Plant and Equipment, Net 27.5K USD
Operating Lease, Right-of-Use Asset 127K USD -35.1%
Intangible Assets, Net (Excluding Goodwill) 63.4M USD
Goodwill 25.8M USD +1432%
Assets 135M USD +57.7%
Accounts Payable, Current 4.97M USD +125%
Accrued Liabilities, Current 410K USD +87.2%
Liabilities, Current 33.5M USD +114%
Deferred Income Tax Liabilities, Net 571K USD
Operating Lease, Liability, Noncurrent 59K USD -59.8%
Other Liabilities, Noncurrent 7.29M USD
Liabilities 45.8M USD +190%
Retained Earnings (Accumulated Deficit) -206M USD -8.23%
Stockholders' Equity Attributable to Parent -6.3M USD -169%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 27.9M USD +233%
Liabilities and Equity 135M USD +57.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -819K USD +78.2%
Net Cash Provided by (Used in) Financing Activities 700K USD -79.3%
Net Cash Provided by (Used in) Investing Activities 88.2K USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 2.55M shares -46.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.5M USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 22K USD +144%
Deferred Tax Assets, Valuation Allowance 37.6M USD +12.6%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0 pure -100%
Deferred Tax Assets, Gross 39.6M USD +18.2%
Operating Lease, Liability 141K USD -34.3%
Depreciation 14.6K USD -50.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -15.8M USD -17.8%
Lessee, Operating Lease, Liability, to be Paid 149K USD -36.6%
Property, Plant and Equipment, Gross 87.8K USD 0%
Operating Lease, Liability, Current 136K USD +70.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 60.6K USD -31.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 88.8K USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.85K USD -58.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 60.6K USD -31.8%
Deferred Tax Assets, Operating Loss Carryforwards 29.6M USD +28.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 228M USD +15%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 34.2K USD +18%
Deferred Tax Assets, Net of Valuation Allowance 1.9M USD +3865%
Share-based Payment Arrangement, Expense 632K USD -39.3%
Interest Expense 79.7K USD +314%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%